EVP, Global Research and CSO of Vertex Pharmaceuticals Inc (30-Year Financial, Insider Trades) David Altshuler (insider trades) sold 2,330 shares of VRTX on 08/03/2020 at an average price of $278.24 a share. The total sale was $648,299.
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Its products include SYMDEKO, ORKAMBI, and KALYDECO. Vertex Pharmaceuticals Inc has a market cap of $71.17 billion; its shares were traded at around $273.23 with a P/E ratio of 34.48 and P/S ratio of 13.31.
CFO Recent Trades:
- EVP & CFO Charles F Jr Wagner sold 700 shares of VRTX stock on 07/10/2020 at the average price of $293.15. The price of the stock has decreased by 6.8% since.
Directors and Officers Recent Trades:
- EVP, Chief Patient Officer Amit Sachdev sold 1,941 shares of VRTX stock on 08/03/2020 at the average price of $278.28. The price of the stock has decreased by 1.81% since.
- SVP & Controller Paul M Silva sold 809 shares of VRTX stock on 08/03/2020 at the average price of $278.3. The price of the stock has decreased by 1.82% since.
- EVP, Chief Adm, Leg & BD Off Michael Parini sold 2,330 shares of VRTX stock on 08/03/2020 at the average price of $278.28. The price of the stock has decreased by 1.81% since.
- EVP, Chief Commercial Officer Stuart A Arbuckle sold 1,553 shares of VRTX stock on 08/03/2020 at the average price of $278.39. The price of the stock has decreased by 1.85% since.
- EVP, Global Research and CSO David Altshuler sold 2,330 shares of VRTX stock on 08/03/2020 at the average price of $278.24. The price of the stock has decreased by 1.8% since.
For the complete insider trading history of VRTX, click here
.
